HopeStage
Back to all studies
RecruitingNCT05962216

Real-world brexpiprazole use in schizophrenia and depression

About this titleRead the official source — NCT05962216
Observational studyAges 18–65China
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Hong KongSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 1, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
40
Sponsor
Dr. Albert Kar-Kin Chung
Sponsor type
Individual investigator
Study type
Observational
Intervention type
Drug
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT05962216
Official title
Show the full official title

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study

Recruitment & locations

Currently recruiting

Hong Kong, Hong Kong · China

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dr. Albert Kar-Kin Chung.

Does this study involve medication?

Yes. The study involves medication, including Brexpiprazole.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies